This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Cardiovascular System  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Genetics  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Arnon Blum, MD; Oxana Podovitzky, MD; Julia Sheiman, MD; Moshe Khasin, BSc

Arch Intern Med. 2009;169(20):1925-1926.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Fabry disease is an X-linked disorder of glycosphingolipid catabolism that results from deficient activity of the lysosomal enzyme -galactosidase A in the vascular smooth muscle, the myocardium, the central nervous system, and epithelial cells of the glomeruli, causing accumulation of globotriaosylceramide, the glycosphingolipid substrate for this enzyme. Five years ago we published a case report of a 26-year-old man with Fabry disease who had first-degree atrioventricular (AV) block with right bundle branch block and diastolic dysfunction with a restrictive pattern. In the last few years he was treated with -galactosidase A. Recently he was readmitted for left leg cellulitis, and surprisingly we found that his electrocardiogram and echocardiogram patterns were improved, with the disappearance of the AV block and diastolic dysfunction.

Report of a Case

A 34-year-old patient was admitted for recurrent left leg cellulitis. He was hospitalized in our department 5 . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?